Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer-Reference-Cited by-同舟云学术

Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer

Published:2013-11-12 Issue:5 Volume:120 Page:642-651
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Welslau Manfred¹,Diéras Veronique²,Sohn Joo-Hyuk³,Hurvitz Sara A.⁴,Lalla Deepa⁵,Fang Liang⁵,Althaus Betsy⁵,Guardino Ellie⁵,Miles David⁶

Affiliation:

1. Medical Office Hematology; Aschaffenburg Germany

2. Institut Curie; Paris France

3. Yonsei University College of Medicine; Seoul South Korea

4. UCLA Jonsson Comprehensive Cancer Center and Translational Research in Oncology; Los Angeles California

5. Genentech, Inc.; South San Francisco California

6. Mount Vernon Cancer Centre; Northwood United Kingdom

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28465/fullpdf

Reference27 articles.

1. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate;Lewis Phillips;Cancer Res,2008

2. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer;Junttila;Breast Cancer Res Treat,2011

3. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer;Barok;Cancer Lett,2011

4. Trastuzumab emtansine for HER2-positive advanced breast cancer;Verma;N Engl J Med,2012

5. Patient-reported outcomes in cancer: a review of recent research and policy initiatives;Lipscomb;CA Cancer J Clin,2007

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of the ESMO Magnitude of Clinical Benefit Scale to assess the clinical benefit of antibody drug conjugates in solid cancer: a systematic descriptive analysis of phase III and pivotal phase II trials;BMJ Open;2024-06

2. Utilization and safety of trastuzumab emtansine (T-DM1): a nationwide population-based study using the French National Health Data System;ESMO Real World Data and Digital Oncology;2024-06

3. Elderly patients with advanced HER2-positive breast cancer with liver metastases benefit from low dose disitamab vedotin (RC48): case series and literature review;Anti-Cancer Drugs;2024-05-03

4. Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review;Breast Cancer Research;2024-03-29

5. Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study;Cancer Research and Treatment;2023-12-20